Related references
Note: Only part of the references are listed.Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
B. Jonsson et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Potential Clinical and Economic Impact of Nonadherence with Osteoporosis Medications
Mickael Hiligsmann et al.
CALCIFIED TISSUE INTERNATIONAL (2010)
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass
D. L. Kendler et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis
I. Imaz et al.
OSTEOPOROSIS INTERNATIONAL (2010)
Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates
Becky A. Briesacher et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Incorporating adherence into health economic modelling of osteoporosis
O. Strom et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Fracture outcomes related to persistence and compliance with oral bisphosphonates
Arlene M. Gallagher et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2008)
Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD
E. Michael Lewiecki et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2007)
Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis
Prajesh Kothawala et al.
MAYO CLINIC PROCEEDINGS (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases
Ethel S. Siris et al.
MAYO CLINIC PROCEEDINGS (2006)
Assessment of compliance with osteoporosis treatment and its consequences in a managed care population
KF Huybrechts et al.
BONE (2006)
Adherence, patient preference and dosing frequency: Understanding the relationship
JY Reginster et al.
BONE (2006)
Denosumab in postmenopausal women with low bone mineral density
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
An assessment of patient preference and adherence to treatment with Wellbutrin SR: A web-based survey
AL Granger et al.
JOURNAL OF AFFECTIVE DISORDERS (2006)
Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer
L Fallowfield et al.
ANNALS OF ONCOLOGY (2006)
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength
PJ Kostenuik
CURRENT OPINION IN PHARMACOLOGY (2005)
Beliefs about antidepressant medications in primary care patients - Relationship to self-reported adherence
C Brown et al.
MEDICAL CARE (2005)
Bone safety of long-term bisphosphonate treatment
G Rodan et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women
PJ Bekker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART
R Horne et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2004)
The impact of compliance with osteoporosis therapy on fracture rates in actual practice
JJ Caro et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Share Paper
